Video

Dr. Scott T. Tagawa on radium-223 in prostate cancer

Author(s):

Urology Times staff

Scott T. Tagawa, MD, provides expert insight on radium-223 (Xofigo), highlighting pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent. Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.

Related Videos
Dr Louise Kostos answers a question during a Zoom video interview
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Avoidance of prostate cancer screening linked to increased risk of PCSM
March 21st 2025

Avoidance of prostate cancer screening linked to increased risk of PCSM

Hannah Clarke
“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Exercise may improve erectile function in men with prostate cancer
March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke
“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke
The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.
© 2025 MJH Life Sciences

All rights reserved.